Literature DB >> 22609035

Antigenic and immunogenic properties of recombinant hemagglutinin proteins from H1N1 A/Brisbane/59/07 and B/Florida/04/06 when produced in various protein expression systems.

Felix W Santiago1, Kris Lambert Emo, Theresa Fitzgerald, John J Treanor, David J Topham.   

Abstract

Antibodies directed against the influenza hemagglutinin (HA) protein largely mediate virus neutralization and confer protection against infection. Consequently, many studies and assays of influenza vaccines are focused on HA-specific immune responses. Recombinant HA (rHA) proteins can be produced in a number of protein expression and cell culture systems. These range from baculovirus infection of insect cell cultures, to transient transfection of plants, to stably transfected human cell lines. Furthermore, the rHA proteins may contain genetic modifications, such as histidine tags or trimerization domains, intended to ease purification or enhance protein stability. However, no systematic study of these different forms of the HA protein have been conducted. It is not clear which, if any, of these different protein expression systems or structural modifications improve or diminish the biological behavior of the proteins as immunogens or antigens in immune assays. Therefore we set out to perform systematic evaluation of rHA produced in different proteins expression systems and with varied modifications. Five rHA proteins based on recent strains of seasonal influenza A and five based on influenza B HA were kindly provided by the Biodefense and Emerging Infections Reagent Repository (BEIR). These proteins were evaluated in a combination of biochemical and structural assays, in vitro humoral and cellular immune assays, and in an animal vaccination model. Marked differences in the behavior of the individual proteins was evident suggesting that they are not equal when being used to detect an immune response. They were, nevertheless, similar at eliciting neutralizing antibody responses.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22609035      PMCID: PMC3379008          DOI: 10.1016/j.vaccine.2012.05.005

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  64 in total

1.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Authors:  Davide Corti; Amorsolo L Suguitan; Debora Pinna; Chiara Silacci; Blanca M Fernandez-Rodriguez; Fabrizia Vanzetta; Celia Santos; Catherine J Luke; Fernando J Torres-Velez; Nigel J Temperton; Robin A Weiss; Federica Sallusto; Kanta Subbarao; Antonio Lanzavecchia
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

2.  Glycosylation of the hemagglutinin modulates the sensitivity of H3N2 influenza viruses to innate proteins in airway secretions and virulence in mice.

Authors:  Michelle D Tate; Emma R Job; Andrew G Brooks; Patrick C Reading
Journal:  Virology       Date:  2011-02-24       Impact factor: 3.616

3.  Studies on influenza haemagglutinin fusion peptide mutants generated by reverse genetics.

Authors:  K J Cross; S A Wharton; J J Skehel; D C Wiley; D A Steinhauer
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

4.  Influenza virus infection of desialylated cells.

Authors:  S J Stray; R D Cummings; G M Air
Journal:  Glycobiology       Date:  2000-07       Impact factor: 4.313

5.  Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice.

Authors:  Pan Tao; Mengcheng Luo; Dandan Zhu; Sanfu Qu; Zhenhua Yang; Meng Gao; Deyin Guo; Zishu Pan
Journal:  Viral Immunol       Date:  2009-07       Impact factor: 2.257

6.  Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus.

Authors:  Chih-Jen Wei; Ling Xu; Wing-Pui Kong; Wei Shi; Kevin Canis; James Stevens; Zhi-Yong Yang; Anne Dell; Stuart M Haslam; Ian A Wilson; Gary J Nabel
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

7.  Expression of the influenza virus haemagglutinin in insect cells by a baculovirus vector.

Authors:  K Kuroda; C Hauser; R Rott; H D Klenk; W Doerfler
Journal:  EMBO J       Date:  1986-06       Impact factor: 11.598

8.  Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades.

Authors:  Karoline Bragstad; Cyril J Martel; Joakim S Thomsen; Kim L Jensen; Lars P Nielsen; Bent Aasted; Anders Fomsgaard
Journal:  Influenza Other Respir Viruses       Date:  2010-11-03       Impact factor: 4.380

9.  Expression and purification of an influenza hemagglutinin--one step closer to a recombinant protein-based influenza vaccine.

Authors:  Keyang Wang; Kathleen M Holtz; Karl Anderson; Richard Chubet; Wafaa Mahmoud; Manon M J Cox
Journal:  Vaccine       Date:  2005-11-10       Impact factor: 3.641

Review 10.  Virus glycosylation: role in virulence and immune interactions.

Authors:  David J Vigerust; Virginia L Shepherd
Journal:  Trends Microbiol       Date:  2007-03-29       Impact factor: 17.079

View more
  5 in total

1.  Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system.

Authors:  Irina Margine; Peter Palese; Florian Krammer
Journal:  J Vis Exp       Date:  2013-11-06       Impact factor: 1.355

2.  Engineered Nanoparticle Applications for Recombinant Influenza Vaccines.

Authors:  Zachary R Sia; Matthew S Miller; Jonathan F Lovell
Journal:  Mol Pharm       Date:  2020-08-17       Impact factor: 4.939

3.  Multi-Dimensional Measurement of Antibody-Mediated Heterosubtypic Immunity to Influenza.

Authors:  Jiong Wang; Shannon P Hilchey; Ollivier Hyrien; Nelson Huertas; Sheldon Perry; Manojkumar Ramanunninair; Doris Bucher; Martin S Zand
Journal:  PLoS One       Date:  2015-06-23       Impact factor: 3.240

4.  Hydrophobin fusion of an influenza virus hemagglutinin allows high transient expression in Nicotiana benthamiana, easy purification and immune response with neutralizing activity.

Authors:  Nicolas Jacquet; Catherine Navarre; Daniel Desmecht; Marc Boutry
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

5.  SARS-CoV-2 spike trimer vaccine expressed in Nicotiana benthamiana adjuvanted with Alum elicits protective immune responses in mice.

Authors:  Shi-Jian Song; Heeyeon Kim; Eun Young Jang; Hyungmin Jeon; Hai-Ping Diao; Md Rezaul Islam Khan; Mi-Seon Lee; Young Jae Lee; Jeong-Hyun Nam; Seong-Ryeol Kim; Young-Jin Kim; Eun-Ju Sohn; Inhwan Hwang; Jang-Hoon Choi
Journal:  Plant Biotechnol J       Date:  2022-08-18       Impact factor: 13.263

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.